Intragastric Balloon for Overweight Patients
Authors:
- Diego L. LimaDLDiego L. Lima
- Isabelle D. MontandonIMIsabelle D. Montandon
- JrJRJr
Open Access
- 1 January 2016
- journal article
- Published by The Society of Laparoscopic and Robotic Surgeons in JSLS : Journal of the Society of Laparoscopic & Robotic Surgeons
- Vol. 20 (1)
Abstract
Current treatments for overweight adults include reduced-calorie diet, exercise, behavior modification, and selective use of medications. Many achieve suboptimal results with these measures and progress to obesity. Whether the intragastric balloon (IGB), a reversible device approved for treatment of obesity, is a safe and effective option in overweight adults is less well studied. We conducted a study to prospectively analyze the safety and effectiveness of IGB in overweight adults, to compare the results to a simultaneously studied cohort of obese patients, and to share procedural tips for safe IGB placement and removal. One hundred thirty-nine patients were evaluated in this prospective, nonrandomized study. Twenty-six overweight [body mass index (BMI), 26–30)] and 113 obese (BMI > 30) patients underwent outpatient, endoscopic IGB placement under intravenous sedation. The IGB was filled with a 550–900 mL (average, 640 mL) solution of saline, radiological contrast, and methylene blue, with an approximate final proportion of 65:2:1. The patients were followed up at 1–2 weeks and then monthly for 6 months. At 6 months, they underwent IGB removal via an esophageal overtube to optimize safety, and then they were observed for 6 more months. IGB time was 190 ± 36 d in the overweight patients and 192 ± 43 d in the obese patients. Symptoms of IGB intolerance included nausea and pain, which were transiently present in 50–95% of patients for several days, and necessitated early IGB removal in 6% of patients. There were no procedure-related complications and no IGB-related esophagitis, erosion, perforation, or obstruction. The percentage of excess weight loss (EWL%) was 96 ± 54% in the overweight group and 41 ± 26% in the obese group (P < 0.001). In overweight adults failing standard treatments, IGB placement for 6 months had an acceptable safety profile and excellent weight loss.Keywords
This publication has 33 references indexed in Scilit:
- Nonsurgical and Surgical Treatment of ObesityAnesthesiology Clinics of North America, 2005
- What Becomes of Patients One Year after the Intragastric Balloon has been Removed?Obesity Surgery, 2005
- Endoscopic Treatments for Obesity: Past, Present and FutureGastroenterology Clinics of North America, 2005
- Bariatric SurgeryJAMA, 2004
- Brazilian Multicenter Study of the Intragastric BalloonObesity Surgery, 2004
- Intragastric Balloon for "Non-Morbid" Obesity: A Retrospective Evaluation of Tolerance and EfficacyObesity Surgery, 2004
- Drug Treatment of ObesityReviews in Endocrine and Metabolic Disorders, 2001
- Obesity: preventing and managing the global epidemic. Report of a WHO consultation.2000
- Obesity and the gastric balloon: a comprehensive workshopGastrointestinal Endoscopy, 1987
- INTRAGASTRIC BALLOON AS AN ARTIFICIAL BEZOAR FOR TREATMENT OF OBESITYThe Lancet, 1982